Proteon Therapeutics's - PRTO market analysis on 19th January 2021

Transaction Date	Recipient	Shares	Type	Price	Value
22nd December 2020	Management Inc. Opaleye	496,277	Open or private purchase	$8.06	$3,999,992.62
22nd December 2020	Management Inc. Opaleye	657	Open or private purchase	$5.19	$3,412.98
22nd December 2020	Management Inc. Opaleye	15,900	Open or private purchase	$5.19	$82,597.32
21st December 2020	Management Inc. Opaleye	51,400	Open or private purchase	$5.24	$269,305.16
21st December 2020	Management Inc. Opaleye	2,059	Open or private purchase	$5.24	$10,787.92
18th December 2020	Management Inc. Opaleye	35,000	Open or private purchase	$5.31	$185,941.00
18th December 2020	Management Inc. Opaleye	1,400	Open or private purchase	$5.31	$7,437.64
10th December 2020	John Gordon Freund	56,327	Other acquisition or disposition	$0.00
10th December 2020	John Gordon Freund	118,735	Other acquisition or disposition	$0.00
3rd December 2020	John Gordon Freund	47,886	Open or private sale	$23.39	$1,120,197.20

Proteon Therapeutics

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001.

Ticker: PRTO

Sector: Health Technology

Industry: Biotechnology

SEC Central Index Key (CIK): 1359931

Employees: 17

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis